Diagnostic Medical Systems SA (ALDMS) - Net Assets
Based on the latest financial reports, Diagnostic Medical Systems SA (ALDMS) has net assets worth €20.66 Million EUR (≈ $24.16 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€62.52 Million ≈ $73.09 Million USD) and total liabilities (€41.85 Million ≈ $48.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Diagnostic Medical Systems SA (ALDMS) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €20.66 Million |
| % of Total Assets | 33.05% |
| Annual Growth Rate | 3.57% |
| 5-Year Change | 1.11% |
| 10-Year Change | -26.91% |
| Growth Volatility | 27.32 |
Diagnostic Medical Systems SA - Net Assets Trend (2009–2025)
This chart illustrates how Diagnostic Medical Systems SA's net assets have evolved over time, based on quarterly financial data. See Diagnostic Medical Systems SA liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Diagnostic Medical Systems SA (2009–2025)
The table below shows the annual net assets of Diagnostic Medical Systems SA from 2009 to 2025. For live valuation and market cap data, see ALDMS stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €20.66 Million ≈ $24.16 Million |
+45.91% |
| 2024-12-31 | €14.16 Million ≈ $16.56 Million |
+3.20% |
| 2023-12-31 | €13.72 Million ≈ $16.04 Million |
-24.47% |
| 2022-12-31 | €18.17 Million ≈ $21.24 Million |
-11.10% |
| 2021-12-31 | €20.44 Million ≈ $23.89 Million |
+19.89% |
| 2020-12-31 | €17.05 Million ≈ $19.93 Million |
+14.86% |
| 2019-12-31 | €14.84 Million ≈ $17.35 Million |
-16.99% |
| 2018-12-31 | €17.88 Million ≈ $20.90 Million |
-23.42% |
| 2017-12-31 | €23.35 Million ≈ $27.30 Million |
-17.42% |
| 2016-12-31 | €28.27 Million ≈ $33.05 Million |
+11.87% |
| 2015-12-31 | €25.27 Million ≈ $29.55 Million |
+14.84% |
| 2014-12-31 | €22.01 Million ≈ $25.73 Million |
+63.37% |
| 2013-12-31 | €13.47 Million ≈ $15.75 Million |
-3.66% |
| 2012-12-31 | €13.98 Million ≈ $16.35 Million |
+57.02% |
| 2011-12-31 | €8.90 Million ≈ $10.41 Million |
-20.25% |
| 2010-12-31 | €11.17 Million ≈ $13.05 Million |
-5.24% |
| 2009-12-31 | €11.78 Million ≈ $13.78 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Diagnostic Medical Systems SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 586500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €31.61 Million | 165.19% |
| Other Comprehensive Income | €-14.43 Million | -75.42% |
| Other Components | €2.13 Million | 11.11% |
| Total Equity | €19.14 Million | 100.00% |
Diagnostic Medical Systems SA Competitors by Market Cap
The table below lists competitors of Diagnostic Medical Systems SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Duxton Farms Ltd
AU:DBF
|
$34.49 Million |
|
Tingsvalvet Fastighets AB
ST:TINGS-A
|
$34.51 Million |
|
Osangjaiel Co. Ltd
KQ:053980
|
$34.52 Million |
|
Nexam Chemical Holding AB
ST:NEXAM
|
$34.52 Million |
|
Fortune Bay Corp
V:FOR
|
$34.47 Million |
|
Panstar Enterprise Co.Ltd
KQ:054300
|
$34.46 Million |
|
JOSAPAR Joaquim Oliveira S.A. Participações
SA:JOPA3
|
$34.45 Million |
|
Kalamazoo Resources Ltd
AU:KZR
|
$34.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diagnostic Medical Systems SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,836,000 to 19,137,000, a change of 6,301,000 (49.1%).
- Net loss of 167,000 reduced equity.
- New share issuances of 6,594,000 increased equity.
- Other comprehensive income decreased equity by 3,108,000.
- Other factors increased equity by 2,982,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-167.00K | -0.87% |
| Share Issuances | €6.59 Million | +34.46% |
| Other Comprehensive Income | €-3.11 Million | -16.24% |
| Other Changes | €2.98 Million | +15.58% |
| Total Change | €- | 49.09% |
Book Value vs Market Value Analysis
This analysis compares Diagnostic Medical Systems SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.31x to 1.77x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €4.12 | €1.27 | x |
| 2010-12-31 | €3.52 | €1.27 | x |
| 2011-12-31 | €1.89 | €1.27 | x |
| 2012-12-31 | €2.15 | €1.27 | x |
| 2013-12-31 | €1.60 | €1.27 | x |
| 2014-12-31 | €2.56 | €1.27 | x |
| 2015-12-31 | €1.30 | €1.27 | x |
| 2016-12-31 | €1.60 | €1.27 | x |
| 2017-12-31 | €1.48 | €1.27 | x |
| 2018-12-31 | €1.12 | €1.27 | x |
| 2019-12-31 | €0.91 | €1.27 | x |
| 2020-12-31 | €1.06 | €1.27 | x |
| 2021-12-31 | €1.16 | €1.27 | x |
| 2022-12-31 | €0.97 | €1.27 | x |
| 2023-12-31 | €0.71 | €1.27 | x |
| 2024-12-31 | €0.71 | €1.27 | x |
| 2025-12-31 | €0.72 | €1.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Diagnostic Medical Systems SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.33%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 3.27x
- Recent ROE (-0.87%) is above the historical average (-21.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -51.88% | -38.75% | 0.79x | 1.70x | €-7.24 Million |
| 2010 | -52.85% | -32.04% | 0.84x | 1.96x | €-6.95 Million |
| 2011 | -26.62% | -11.01% | 1.01x | 2.39x | €-3.22 Million |
| 2012 | 1.86% | 0.92% | 1.21x | 1.67x | €-1.13 Million |
| 2013 | -7.26% | -4.36% | 0.94x | 1.76x | €-2.31 Million |
| 2014 | -5.37% | -4.45% | 0.63x | 1.93x | €-3.14 Million |
| 2015 | -11.04% | -7.37% | 0.78x | 1.91x | €-5.11 Million |
| 2016 | -5.43% | -3.60% | 0.75x | 2.02x | €-3.82 Million |
| 2017 | -3.62% | -3.13% | 0.68x | 1.71x | €-3.20 Million |
| 2018 | -30.21% | -22.42% | 0.66x | 2.04x | €-7.26 Million |
| 2019 | -22.09% | -10.44% | 0.77x | 2.75x | €-4.70 Million |
| 2020 | -30.78% | -16.28% | 0.70x | 2.69x | €-6.94 Million |
| 2021 | -20.69% | -10.68% | 0.68x | 2.83x | €-5.75 Million |
| 2022 | -43.55% | -19.34% | 0.65x | 3.44x | €-8.39 Million |
| 2023 | -39.94% | -11.21% | 0.86x | 4.13x | €-6.18 Million |
| 2024 | -22.44% | -6.25% | 0.85x | 4.20x | €-4.16 Million |
| 2025 | -0.87% | -0.33% | 0.80x | 3.27x | €-2.08 Million |
Industry Comparison
This section compares Diagnostic Medical Systems SA's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $18,708,962
- Average return on equity (ROE) among peers: -155.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diagnostic Medical Systems SA (ALDMS) | €20.66 Million | -51.88% | 2.03x | $34.47 Million |
| Affluent Medical SAS (AFME) | $31.47 Million | -49.74% | 0.80x | $110.43 Million |
| Biosynex (ALBIO) | $66.29 Million | 47.32% | 0.90x | $15.74 Million |
| Bluelinea SA (ALBLU) | $2.68 Million | -60.39% | 3.04x | $9.00 Million |
| Carmat (ALCAR) | $1.40 Million | -1250.42% | 5.16x | $6.37 Million |
| Eurobio Scientific SA (ALERS) | $18.07 Million | -40.63% | 1.08x | $236.10 Million |
| Ikonisys SA (ALIKO) | $15.73 Million | -14.41% | 0.33x | $21.30 Million |
| Implanet SA (ALIMP) | $-174.00K | 0.00% | 0.00x | $28.16 Million |
| Mediantechn (ALMDT) | $-7.25 Million | 0.00% | 0.00x | $183.29 Million |
| Mauna Kea Technologies SAS (ALMKT) | $40.16 Million | -32.51% | 0.22x | $28.43 Million |
About Diagnostic Medical Systems SA
Diagnostic Medical Systems S.A. engages in the design, development, manufacture, and sale of medical imaging systems in France. It offers ADAM, in-house software suite; R and F solutions; bone densitometry; chest and bone room; mobile; c-arm; retrofit kit; and mammography equipment. The company was founded in 1979 and is headquartered in Gallargues-le-Montueux, France.